

AMENDMENT UNDER 37 C.F.R. §1.116
U.S. Appln. No. 09/767,943

Please enter the following amended claims 71-73, 80, 82, 83 and 85:

D1 Claim ~~71~~²⁴ (amended). The process according to claim ~~73~~²³, wherein said non-human animal is a mammal.

D2 Claim ~~72~~²⁵ (amended). The process according to claim ~~73~~²³, wherein said mammal is selected from the group consisting of cows, sheep, horses, pigs, goats, rabbits, dogs, and cats.


D3 Claim ~~73~~²³ (twice amended). A process for treating an eye, comprising:
topically applying an azalide antibiotic to an eye of a non-human animal in an amount effective to treat infection in a tissue of the eye, wherein said topically applying comprises supplying a depot of a composition containing said azalide antibiotic on the eye.

D4 Claim ~~80~~²² (twice amended). The process according to claim ~~73~~²³, wherein said composition further comprises an additional medicament.

D5 Claim ~~82~~²⁴ (twice amended). The process according to claim ~~73~~²³, wherein said eye is suffering from at least one condition selected from the group consisting of conjunctivitis, ophthalmic neonatorum, trachoma, corneal ulcers, keratitis, keratoconjunctivitis, endophthalmitis, infectious uveitis and combinations thereof, and said amount of said azalide antibiotic is therapeutically effective to treat said condition.

AMENDMENT UNDER 37 C.F.R. §1.116
U.S. Appln. No. 09/767,943

³⁵ Claim ~~33~~ (Three times Amended). The process according to claim ~~73~~²³, wherein said azalide antibiotic is a compound of formula (I):



(I)

wherein R¹ and R² each independently represent a hydrogen atom or methyl group.

³⁷ Claim ~~35~~ (twice amended). The process according to claim ~~73~~²³, wherein said applying provides a therapeutically effective concentration of azalide antibiotic within a tissue of the eye for at least 8 hours.

D7